President Clinton rejected the Medicare reform proposal presented by Sen. John Breaux (D-LA) and his fellow policy makers on the National Bipartisan Commission on the Future of Medicare.
President Clinton rejected the Medicare reform proposal presented by Sen. John Breaux (D-LA) and his fellow policy makers on the National Bipartisan Commission on the Future of Medicare.
"The plan offered by Senator Breaux and his colleagues included some very strong elements, which should be seriously considered by Congress," Clinton said. "However, I believe their approach falls short in several respects."
Among those shortcomings, according to Clinton, are the lack of a prescription drug benefit, the potential to raise premiums for those in the traditional Medicare program, a raise in the age of eligibility for Medicare (from 65 to 67) and no solid commitment to financing a Medicare trust fund.
Clinton said his advisors will draft a plan for Congress to consider. Almost certainly, Clinton's plan will earmark 15% of the federal surplus to a trust fund for Medicare and include a prescription drug benefit. It is unclear, however, whether his plan will include a universal Medicare prescription drug benefit, which some industry experts have predicted could cost the nation more than $30 billion.
Despite Clinton's lack of support, Breaux indicated that he might still introduce Medicare reform legislation for debate this fall. PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Recent Developments in Pharmaceutical Validation
November 1st 2024Explore the latest pharmaceutical validation developments with industry experts from Barry-Wehmiller Design Group, Kneat Solutions, and No Deviation. You’ll gain valuable data-driven insights and discover emerging trends from the State of Validation 2024 industry report that are shaping the validation landscape.